IMPLICYTE, INC.

Biotech · Private

Engineered oncolytic vesicular stomatitis viruses (VSV) expressing immunostimulatory transgenes for glioblastoma treatment

Grants
$399K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of Immunostimulatory Virotherapy Without Neurotoxicity for the Treatment of Brain Malignancies$399,335
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2713Immune Response BioPharma, Inc.—$1.0B
2714Foghorn Therapeutics——
2715COGNOSCI, INC.——
2716IMPLICYTE, INC.——
2717OnRamp Digital, Inc.—$360K
2718Mendra——
2719GLYTR THERAPEUTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Armed Chimeric Oncolytic Virusesapplication
  • Armed Chimeric Oncolytic Virusesapplication
  • Armed Chimeric Oncolytic Virusesapplication
  • Armed Chimeric Oncolytic Virusesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.